MedImmune LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00192452
- Locations
- ๐บ๐ธ
MDS Pharma Services (US) Inc., Phoenix, Arizona, United States
๐บ๐ธNorthwest Kinetics, Tacoma, Washington, United States
๐บ๐ธWake Forest University School of Medicine, Winston-Salem, North Carolina, United States
Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00192361
- Locations
- ๐ซ๐ฎ
Kauppakatu Clinic, Tampere, Finland
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
Phase 3
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2160
- Registration Number
- NCT00192400
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2229
- Registration Number
- NCT00192257
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children
Phase 3
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 3000
- Registration Number
- NCT00192244
- Locations
- ๐จ๐ณ
The Prince of Wales Hospital, Hong Kong, China
Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children
Phase 3
Completed
- Conditions
- Respiratory Tract Infections
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2200
- Registration Number
- NCT00192205
- Locations
- ๐ช๐ธ
Hospital de Txagorritxu, Vitoria, Spain
๐ฎ๐ฑSchneider Children's Medical Center of Israel, Petah-Tikva, Israel
Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2400
- Registration Number
- NCT00192426
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: CAIV-TOther: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2903
- Registration Number
- NCT00192283
- Locations
- ๐ซ๐ฎ
Tampere University Medical School, Tampere, Finland
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluMistOther: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT00192491
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluMist
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 345
- Registration Number
- NCT00192140
- Locations
- ๐บ๐ธ
Center for Vaccine Development, Saint Louis, Missouri, United States
๐บ๐ธCreighton University Medical Center, Omaha, Nebraska, United States
๐บ๐ธUniversity of Virginia, Elson Student Health Center, Charlottesville, Virginia, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath